Abstract
Double-blind, randomised placebo-controlled, adaptive phase iib trial with vafidemstat in borderline personality disorder – aggregated baseline characteristics/demographics and safety
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have